Lexicon Pharmaceuticals, Inc. (LXRX) stock
LXRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/3087% above fair value
$1.72−0.06 (-3.37%)
Close on Nov 18, 2026Market cap $765.32MP/E –Yield –
Lexicon Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lexicon Pharmaceuticals's pe ratio was 13.6× on Oct 29, 2021, against 2.3× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2021 | Oct 29, 2021 | 13.6× | +7.7 |
| 2020 | Oct 30, 2020 | 5.8× | +2.8 |
| 2019 | Dec 31, 2019 | 3.1× | – |
See a number that looks wrong?